1. Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress.
- Author
-
Williamson LE, Reeder KM, Bailey K, Tran MH, Roy V, Fouch ME, Kose N, Trivette A, Nargi RS, Winkler ES, Kim AS, Gainza C, Rodriguez J, Armstrong E, Sutton RE, Reidy J, Carnahan RH, McDonald WH, Schoeder CT, Klimstra WB, Davidson E, Doranz BJ, Alter G, Meiler J, Schey KL, Julander JG, Diamond MS, and Crowe JE Jr
- Subjects
- Animals, Antibodies, Monoclonal immunology, Antibodies, Monoclonal isolation & purification, Antibodies, Neutralizing immunology, Antigens, Viral immunology, Cell Line, Chikungunya virus immunology, Encephalitis Virus, Eastern Equine immunology, Encephalomyelitis, Equine immunology, Encephalomyelitis, Equine virology, Epitope Mapping, Female, Horses, Humans, Hydrogen-Ion Concentration, Joints pathology, Male, Mice, Inbred C57BL, Models, Biological, Protein Binding, RNA, Viral metabolism, Receptors, Fc metabolism, Temperature, Virion metabolism, Virus Internalization, Mice, Alphavirus immunology, Antibodies, Viral immunology, Cross Reactions immunology, Viral Proteins immunology, Virus Release physiology
- Abstract
Alphaviruses cause severe arthritogenic or encephalitic disease. The E1 structural glycoprotein is highly conserved in these viruses and mediates viral fusion with host cells. However, the role of antibody responses to the E1 protein in immunity is poorly understood. We isolated E1-specific human monoclonal antibodies (mAbs) with diverse patterns of recognition for alphaviruses (ranging from Eastern equine encephalitis virus [EEEV]-specific to alphavirus cross-reactive) from survivors of natural EEEV infection. Antibody binding patterns and epitope mapping experiments identified differences in E1 reactivity based on exposure of epitopes on the glycoprotein through pH-dependent mechanisms or presentation on the cell surface prior to virus egress. Therapeutic efficacy in vivo of these mAbs corresponded with potency of virus egress inhibition in vitro and did not require Fc-mediated effector functions for treatment against subcutaneous EEEV challenge. These studies reveal the molecular basis for broad and protective antibody responses to alphavirus E1 proteins., Competing Interests: Declaration of interests J.E.C. has served as a consultant for Luna Biologics, is a member of the Scientific Advisory Board of Meissa Vaccines, and is Founder of IDBiologics. The Crowe laboratory at Vanderbilt University Medical Center has received unrelated sponsored research agreements from IDBiologics and AstraZeneca. M.S.D. is a consultant for Inbios, Vir Biotechnology, NGM Biopharmaceuticals, and Carnival Corporation and on the Scientific Advisory Boards of Moderna and Immunome. The Diamond laboratory at Washington University School of Medicine has received sponsored research agreements from Emergent BioSolutions, Moderna, and Vir Biotechnology. All other authors report no conflicts. M.E.F., E.D., and B.J.D. are employees of Integral Molecular and B.J.D. is a shareholder. G.A. is a founder and the Chief Scientific Officer (Consulting) of Seromyx., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF